Company Encyclopedia
View More
name
Vivani Medical
VANI.US
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease and medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in clinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature and subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant for metabolic diseases in cats. The company is headquartered in Alameda, California.
1.387 T
VANI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Director and 10% Owner Gregg Williams Acquires Common Shares of Vivani Medical Inc

    Gregg Williams, a Director and 10% Owner of Vivani Medical Inc., has acquired common shares of the company. The acquisition was reported through EDGAR by the U.S. Securities and Exchange Commission on December 16, 2025.

    Reuters·
    US
    VANI
    -1.57%
    Reuters·
    US
    VANI
    -1.57%

    Vivani Medical Inc. unveils presentation on subdermal semaglutide implant for chronic weight management

    Vivani Medical Inc. has unveiled a presentation on its subdermal semaglutide implant, NPM-139, for chronic weight management. The implant offers dosing every 6 to 12 months, unlike current GLP-1 therapies. The LIBERATE-1 study showed positive results in safety and performance. Vivani plans to start clinical trials in 2026 and expects its cash runway to last until 2027. The GLP-1 market is projected to reach $139 billion by 2030.

    Reuters·
    US
    VANI
    -1.57%
    Reuters·
    US
    VANI
    -1.57%

    Vivani Medical’s NPM-139: A Promising Semaglutide Implant with Strong Buy Rating

    H.C. Wainwright analyst Yi Chen reiterated a Buy rating for Vivani Medical's stock (VANI) due to the promising potential of their semaglutide implant, NPM-139, for chronic weight management. The company plans to start a Phase 1 clinical trial in early 2026. Preclinical studies show significant weight loss for over six months. Financial activities have strengthened the company's cash position. Maxim Group also maintained a Buy rating with a $4.00 price target.

    Tip Ranks·
    US
    VANI
    -1.57%
    Tip Ranks·
    US
    VANI
    -1.57%

    Director and 10% Owner Gregg Williams Reports Acquisition of Vivani Medical Inc. Common Shares

    Gregg Williams, a Director and 10% Owner of Vivani Medical Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link provided. This news brief was created by Public Technologies (PUBT) using generative AI and is for informational purposes only.

    Reuters·
    US
    VANI
    -1.57%
    Reuters·
    US
    VANI
    -1.57%

    Vivani Medical’s Innovative Semaglutide Implant and Market Positioning Drive Buy Recommendation

    Analyst Naz Rahman from Maxim Group reiterated a Buy rating for Vivani Medical, maintaining a $4.00 price target. The recommendation is based on Vivani's innovative NPM-139 semaglutide implant, which offers a unique six-month administration cycle, potentially improving patient compliance. The recent acquisition of Metsera by Pfizer highlights the value of long-duration obesity treatments, supporting Vivani's strategy. Vivani's stock price increased by 29.05% over six months, reinforcing the Buy recommendation.

    Tip Ranks·
    US
    VANI
    -1.57%
    Tip Ranks·
    US
    VANI
    -1.57%
    © 2025 Longbridge｜Disclaimer